Table 1.
Patient | Isotype | Diagnosis | Lymphoma response to antiviral therapy | VH | VL | Accession # VH/VL | HCV genotype | E2661 | J6E2 | E1E2 | NS + Core |
---|---|---|---|---|---|---|---|---|---|---|---|
101 | IgM/k | DLBCL | ND | VH1-69 | Vk3-20 | KF895775/6 | ND | Neg | ND | ND | ND |
102 | IgM/k | FL | ND | VH3-48 | Vk1-39 | KF895777/8 | ND | Neg | ND | ND | ND |
103 | Ig*/k | MZL | ND | VH4-59 | Vk3-20 | KF895779/80 | ND | Neg | ND | ND | ND |
104 | IgM/k | DLBCL | ND | VH1-69 | Vk1D-16 | KF895781/2 | ND | Neg | ND | ND | ND |
105 | IgM/k | DLBCL | ND | VH1-69 | Vk3-20 | KF895783/4 | ND | Neg | ND | ND | ND |
106 | IgM/k | NHL | ND | VH4-59 | Vk3-15 | KF895785/6 | ND | Neg | ND | ND | ND |
107 | IgM/k | NA | ND | VH3-21 | Vk1-39 | KF895787/8 | ND | Neg | ND | ND | ND |
108 | IgM/k | NA | ND | VH4-59 | Vk3-15 | KF895789/90 | ND | Neg | Neg | Neg | Neg |
109 | IgM/k | NA | ND | VH4-34 | Vk3-20 | KF895791/2 | ND | Neg | Neg | Neg | Neg |
110 | IgM/k | NA | ND | VH4-59 | Vk3-20 | KF895793/4 | ND | Neg | Neg | Neg | Neg |
111 | IgG/k | NA | ND | VH1-02 | Vk2-30 | KF895795/6 | ND | Neg | Neg | Neg | Neg |
112 | IgM/k | NA | ND | VH4-34 | Vk3-20 | KF895797/8 | ND | Neg | Neg | Neg | Neg |
121 | IgM/k | MALT MZL | Yes | VH1-69 | Vk3-20 | KF895799/800 | 2a/2c | Neg | Neg | Neg | Neg |
122 | IgM/k | SMZL | No | VH4-59 | Vk3D-15 | KF895801/2 | 1b | Neg | Neg | Neg | Neg |
123 | IgM/k | SMZL | Yes | VH1-69 | Vk3-20 | KF895803/4 | 2a/2c | Neg | Neg | Neg | Neg |
124 | IgM/k | MALT MZL | Yes | VH4-30 | Vk3-15 | KF895805/6 | 2a/2c | Neg | Neg | Neg | Neg |
125 | IgM/k | SMZL | Yes | VH3-30 | Vk1-8 | KF895807/8 | 2a/2c | Neg | Neg | Neg | Neg |
126 | IgM/k | MALT MZL | Yes | VH1-69 | Vk3-20 | KF895809/10 | 1b | Neg | Neg | Neg | Neg |
127 | IgM/k | NHL | No | VH1-69 | Vk3-20 | KF895811/2 | 1b | Neg | Neg | Neg | Neg |
DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; Ig*, undetermined heavy chain; MALT, mucosa-associated lymphoid tissue; MZL, marginal zone lymphoma; NA, not available; ND, not done; Neg, negative; NS + Core, HCV nonstructural + core proteins; SMZL, splenic marginal zone lymphoma.